MULTIFACTORIALITY OF ALZHEIMER’S DISEASE: SCIENTIFIC AND SOCIO-ECONOMIC DIMENSION
Open Access
- 11 June 2026
- journal article
- Published by Vinnytsia National Pyrogov Memorial Medical University in Reports of Vinnytsia National Medical University
- Vol. 30 (2) , 357-363
Abstract
The growth of the proportion of elderly people in the population leads to the globalization of Alzheimer’s disease (AD), which is becoming not only a medical but also a serious social, ethical and economic problem of our time. The aim of the study is a comprehensive analysis of the multifactorial nature of AD, taking into account the interaction of genetic, molecular, metabolic factors, as well as a generalization of modern approaches to early diagnosis and treatment of the disease and an assessment of its medical, social and economic impact on society, the healthcare system and patients’ families. The study was conducted in the format of a systematic review of scientific literature using the following sources: PubMed, Scopus, Web of Science and reports of international organizations for the period 2015–2026. As a result of the analysis of modern scientific data, it was established that today there are a number of pathogenetic theories of the development of AD, among which the leading ones are amyloid, tau-protein, glutamatergic, mitochondrial, metabolic and genetic hypotheses, as well as concepts related to oxidative stress and neuroinflammation. The key links of the neurodegenerative process are the accumulation of β-amyloid, pathological hyperphosphorylation of tau-protein, disruption of proteostasis, autophagy and mitophagy, which leads to destabilization of the neuronal cytoskeleton, formation of neurofibrillary tangles, synaptic dysfunction and neuronal death. Neurodegenerative changes are accompanied by disruption of cellular homeostasis and progressive damage of axons, dendrites and synapses, that justifies the need for early implementation of preventive and neuroprotective strategies to slow down the progression of the disease. At the same time, current pharmacotherapeutic approaches to the treatment of AD are mainly symptomatic and aimed at slowing down the progression of cognitive, behavioral and mental manifestations of dementia. Socio-economic analysis has revealed a significant burden on state budgets and families due to direct medical costs, loss of caregivers’ working capacity and a projected increase in costs in the coming decades. Thus, AD is a classic example of a multifactorial pathology that requires an integrated scientific and social approach.Keywords
This publication has 27 references indexed in Scilit:
- Global Societal Burden of Alzheimer’s Disease by Severity: a Targeted Literature ReviewNeurology and Therapy, 2025
- Unraveling the Complexity of Alzheimer’s Disease: Insights into Etiology and Advancements in Treatment StrategiesJournal of Molecular Neuroscience, 2025
- The worldwide costs of dementia in 2019Alzheimer's & Dementia, 2023
- The Costs of Dementia in Europe: An Updated Review and Meta-analysisPharmacoEconomics, 2022
- The monomers, oligomers, and fibrils of amyloid-β inhibit the activity of mitoBKCa channels by a membrane-mediated mechanismBiochimica et Biophysica Acta (BBA) - Biomembranes, 2020
- Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotypeAlzheimer's & Dementia, 2019
- Prevalence and incidence of Alzheimer's disease in Europe: A meta-analysisNeurología (English Edition), 2017
- Protecting the mitochondrial powerhouseTrends in Cell Biology, 2015
- Autophagy and AgingCell, 2011
- Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic PerspectiveCell, 2005